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From the Editor’s Desk
The past few issues have been theme based where
we have covered reams of new information and
technologies on a focused subject. For a change, we
have once again adapted a non-thematic approach
in this issue since a lot of information can be
disseminated by this methodology as well.

leukemia to name a few, we have also shared
information on genetic testing services offered
for alpha thalassemia. In addition, the issue
also includes information about various other
new tests available in different sections of the
department.

This issue contains variety of articles from
Tathology, Microbiology and Radiology.
Apart from increasing awareness on quality
improvements, needle stick injuries, new markers
for sepsis, collection technique for blood cultures
and prognostic markers for acute myeloid

It is hoped that this issue will further enhance
the awareness and education of our physicians in
diagnosing common and rare medical conditions.
Dr Natasha Ali
Haematologist

Provocative Testing for Growth Hormone
Disorders
Dr Noreen Sherazi & Dr Shabnum Khawaja
Chemical Pathology

Introduction
The diagnosis of growth hormone deficiency
(GHD) or excess in a child or adult with impaired
or abnormal growth cannot be made on the basis of
auxological criteria alone, since these are common
to a variety of growth disorders related to different
causes. In our current understanding, any growth
disorder that is caused either by impaired growth
hormone (GH) secretion or by impaired peripheral
action of GH can be classified as GHD and excess
growth hormone secretion is labeled as gigantism in
a child and acromegaly in an adult.
Normal GH secretion shows an episodic circadian
pattern with wide intra- and inter-individual
variation, for this reason random serum GH levels
are of little value and provocative testing of GH
is indicated for biochemical diagnosis of GH
disorders. It can be stimulated by physiological
or pharmacological ways. Sleep, fasting and
exercise are the physiologic stimuli of the GH
release. Pharmacological stimuli include L-dopa,
clonidine, propranolol, glucagon, arginine, GHreleasing hormone (GHRH) and insulin-induced
hypoglycemia. In the diagnosis of GHD, these

pharmological stimuli can be used alone or in a
variety of combinations.
The provocative tests done in Section of Chemical
Pathology, Department of Pathology and
Microbiology are discussed below:
1) For GH Deficiency:
l ‘Growth hormone stimulation test with insulin’
		 or ‘Insulin hypoglycemia test (IHT)’ or
‘Insulin tolerance test (ITT)’
l Growth hormone stimulation with L-DOPA
2) For GH Excess:
l Growth hormone suppression with glucose by
		 Oral glucose tolerance test (OGTT)
Growth Hormone Stimulation Test with Insulin
The patient comes to the laboratory by appointment
and overnight fast for 10-14 hours is mandatory
for the procedure. Test is started by taking consent,
weighing and cannulating the patient for emergency
I/V access. Required dose of insulin is calculated i.e.
0.1 or 0.15 units/kg body weight. 10 cc syringe with
25 per cent dextrose is kept ready. Baseline sample
3
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of glucose and GH is taken and simultaneously
patient’s glycemic status is checked on glucometer.
After that multiple sampling of glucose and GH is
done at 30,45,60,90 and 120 minutes. The test will
be continued further only if blood glucose level
drops below 50 mg/dl or <2.9 mmol or patient is
symptomatic (i.e. there is shivering, irritability,
drowsiness, fweating, confusion, fatigue, hunder,
etc.) If blood glucose level doesn’t drop till 50 mg/
dl or no symptoms at all then test is repeated with
higher insulin dose i.e. 0.15 units /kg taking 45
minutes glucose level as baseline.
Insulin induces hypoglycemia and as a result GH is
released. After stimulation, for a normal individual
GH should increase to a peak value of >10 ng/
ml when hypoglycemia is achieved. If there is GH
deficiency this GH peak would not be observed.
Growth Hormone Stimulation Test with L-DOPA
It is pharmacological stimulus of GH to evaluate GH
deficiency. No appointment is needed. Patient should
fast overnight for the procedure. Consent should be
taken and dose of L-dopa tablet for the patient is
calculated according to weight i.e. 125 mg if weight
is ≤ 15 kg, 250 mg if weight is 16-35 kg and 500
mg if weight is >35 kg body weight. After baseline
sampling for serum GH, the tablet of L-dopa should
be ingested by the patient with few sips of water.
Blood samples are collected at 30, 60, 90 and 120
minutes. Please note that test should be abandoned
if patient vomits out ingested tablet (blue vomitus)
before 60 minutes sample.
After pharmacological stimulation, normally GH
peaks in 30 -120 minutes and its concentration is
far above 7.5ng/ml. Deficiency is suspected if levels
remain below the desired cutoff.
Growth Hormone Suppression with OGTT
When there is clinical suspicion of acromegaly or
gigantism GH secretion becomes autonomous it will
not suppress with hyperglycemia, where as in normal
individuals hyperglycemia causes GH inhibition.
However, it should not be done in diabetic patients
who have suppressed GH due to hyperglycemia. No
prior appointment from the laboratory is required.
Patient should fast overnight. After consent, baseline
samples for GH and glucose is taken. Anhydrous 75g
of glucose in 300 ml of cold water is given to the
patient. Multiple sampling is done at 30, 60, 90 and
120 minutes for GH and glucose.
Normally GH suppresses with hyperglycemia or
4
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glucose load to < 2ng/ml. In case of acromegaly
patient will fail to show suppression and there will be
paradoxical rise in GH concentration.
Please note we are also performing insulin growth
factor 1 (IGF-1) levels at AKUH Clinical Laboratory
for diagnosing various GH disorders.
Frequently asked questions from Chemical
Pathologists regarding GH stimulation with insulin:
Should the test be conducted if a patient comes
with fasting in excess of 14 hours?
Test should not be done because over longer periods of
fasting, liver will start to produced glucose endogenously
by gluconeogenesis will affect the test results.
Should the test be continued if the fasting blood
glucose is high?
Take proper history regarding meal intake and
duration of fasting. Start the test if the fasting is
below diabetic range.
What will you do if the patient’s blood glucose
hasn’t dropped down at 30 minutes and patient is
also not symptomatic?
It means biochemical hypoglycemia not achieved.
Wait till 45 minutes sample and if still high start the
test with second bolus of insulin i.e. 0.15units/kg
body weight.
Should the test be continued if the patient’s blood
glucose hasn’t dropped down at 30 minutes but
patient is irritable or drowsy?
Criteria for proceeding the GH stimulation with
insulin is either biochemical hypoglycemia i.e. 50
mg/dl glucose or signs of hypoglycemia. In this case
we will carry on with the procedure.
What will be the new blood glucose baseline while
giving insulin again?
We will wait till 45 minutes sample, if glucose level
is still high then restart the test with 45 minutes
reading taken as baseline for glucose.
What will you do if on repeating GH stimulation
by insulin, blood glucose does not drop?
It could be due to various reasons; firstly if it is
happening frequently over the past few weeks then
check your insulin vial. If it is closer to expiry, discard
and get a new one. Secondly if this is the first case then
we should suspect insulin resistance in such patients.
Test should be abandoned and a note should be given
or communicate with treating physician directly so
that he is well aware about the failure of test.
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Serum Procalcitonin for Early Sepsis Diagnosis
Dr Sibtain Ahmed
Chemical Pathology

Procalcitonin, a protein that consists of 116
amino acids is a peptide precursor of the hormone
calcitonin. Procalcitonin is also produced by the
neuroendocrine cells of the lung and intestine. It is
released as an acute-phase reactant in response to
pro-inflammatory stimuli, especially of bacterial
origin. Increased levels of procalcitonin in response
to viral infections and noninfectious inflammatory
stimuli (autoimmune diseases and chronic
inflammatory processes) are much less pronounced,
rarely exceeding 0.5 ng/mL. Severe trauma, major
burns, multi-organ failure, or major surgery can
cause procalcitonin elevations in the absence of
sepsis. The optimal cut-off ranges of procalcitonin
are variable and are dependent on the clinical setting
and the site and extent of the infection. Following are
the clinical and diagnostic utilities of procalcitonin.

and viral infections are widely overlapping,
especially in respiratory tract infections. Sometimes
the diagnostic uncertainty still remains, even after
obtaining a complete clinical history, performing
a physical examination and requesting various
radiological/ laboratory investigations. It is often
difficult to differentiate bacterial from viral causes
of sepsis. Serum procalcitonin with more specificity
for differentiating bacterial from viral infections
considerably improves the differential diagnosis in
these cases. Procalcitonin released as an acute-phase
reactant is associated with bacterial endotoxin and
inflammatory cytokines and it does not increase in
viral infections.
Prognostic Marker of Sepsis
Increased levels of procalcitonin are also reported
to be associated with higher SOFA (Sequential
Organ Failure Assessment score) and APACHE
II scores (Acute Physiology and Chronic Health
Evaluation). Serial measurements of serum
procalcitonin can be of greater value in monitoring
response to treatment in septic shock. Decreasing
procalcitonin levels in patients with sepsis indicate
effective treatment of the underlying infection.
Persistently elevated procalcitonin levels indicate
a possible treatment failure. When integrated into
the management of septic patients, procalcitonin
can help clinicians to manage septic patients more
efficiently.

Procalcitonin Kinetics in Sepsis
Serum procalcitonin has been demonstrated to
be an ideal biomarker for differentiating patients
with sepsis from those with systemic inflammatory
reaction not related to infectious cause. Table 1
shows the comparison of procalcitonin with other
biomarkers used to assist sepsis diagnosis.
Differentiates Bacterial from Viral Infection
A commonly encountered situation in the clinical
practice is that the signs and symptoms of bacterial

Table 1. Compares the Kinetics of C-reactive Peptide, Interleukins, Tumor Necrosis Factor-α with Serum Procalcitonin after a
Bacterial Insult

Cytokines (interleukins,
tumor necrosis factor-α)

C-Reactive Protein

Procalcitonin

Rise

1-3 hours

12-24 hours

2-4 hours

Peaks

2 hours

48 hours

8 hours

Relation to Only remain elevated for few
hours
sepsis

Can remain elevated without there being underlying
infection

Persists for as long as the
inflammatory process
continues

Normalize 8 hours

Late

Early
5
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Utility in Paediatrics

Utility in Organ Transplants Rejection

Adding procalcitonin results to clinical assessment
improves the accuracy of the early clinical diagnosis
of sepsis in neonates. It can also be used in the
early diagnosis of bacterial meningitis. It is a useful
biomarker in differentiating bacterial from nonbacterial meningitis.

Procalcitonin possesses both sensitivity and
specificity in identifying infection complications
among patients undergoing solid organ
transplantation. It is useful in differentiating acute
graft rejection after solid organ transplantation from
bacterial infections.

Useful in Neutropenic Patients

Antibiotic Stewardship

Several published studies have shown that the
procalcitonin levels accurately predicted blood
culture positivity in patients with neutropenia.
Procalcitonin measurement also demonstrated the
potential to reduce the number of blood cultures
drawn in the Emergency Department to better
implement resources. Several studies have shown
that the use of procalcitonin in targeting rational
blood culture utilization allows for more directing
allocation of limited health-care resources.

Müller and colleagues have recommended a
procalcitonin guided diagnostic algorithm for
patients with suspected sepsis. This is based on
data available to date that discourages use of
antibiotics at 0.1 - 0.25 ng/mL of procalcitonin
levels. Whereas at the levels of >0.5 ng/
mL use of antibiotics is encouraged. A rising
procalcitonin after starting treatment should
prompt a review of antibiotics or source control
in patients with systemic infections. In four
intervention trials enrolling more than 1200
patients, the success of this algorithm was
measured by clinical outcomes, assuming that,
if the patient recovered without antibiotics, then
there was no serious bacterial illness. Literature
shows reduction in the antibiotic prescription
rate by 40-50 per cent in patients with lower
respiratory tract infection by procalcitonin
guided stewardship. Procalcitonin at low
concentrations can help to differentiate patients
with clinically relevant lower respiratory tract
infection who require antibiotic therapy from
those with viral infection or minor bacterial
infection who do not require antibiotic treatment.

Prediction of Renal Involvement in Paediatric
Urinary Tract Infection
Urinary tract infection (UTI) in young children
carries the risk of parenchymal damage and sequelae.
The location of the infection within the urinary tract
influences decisions regarding both therapeutics and
follow-up. Because clinical features and laboratory
markers of infection at an early age are not specific,
it is difficult to make a distinction between lower
UTI and acute pyelonephritis. Procalcitonin values
have been proved to be more specific for identifying
patients who might develop renal damage.

PCT value

<0.25
ng/ml

0.25-0..49
ng/m
ml

>0..5-1.0
ngg/ml

>1.0
ng/ml

Strongly consider antibiotic initiation in all patients with suspicion of infection

Antibiotic
An
ntibiotic
reccom
mendation
recommendation

Strongly
d
discouraged

Discouraged

Encouraged

Strongly
eencouraged

Figure 1. Algorithm for guidance of antibiotic initiation and modification proposed by Müller B et al. Int J Antimicrobial Agents.
2007, 30S:S16-S23

6

VOL. 40, ISSUE 1

APRIL 2014

TRALI
Dr Farheen Karim
Haematology

TRALI is a syndrome characterized by the
development of new onset acute respiratory
distress with hypoxemia (SpO2 <90% on room
air) during or up to six hours after completion
of a blood transfusion. The incidence of
TRALI has been reported to be one in 2000 to
one in 7500 transfusions. However, it is felt
worldwide that TRALI is an under-recognized
and under-reported entity because of lack of
awareness.
Diagnosis of TRALI
TRALI is a clinical diagnosis. It should be
considered whenever a patient develops hypoxemic
respiratory insufficiency during or shortly after
transfusion of any blood product. The clinical and
radiologic findings in TRALI are as follows:
Clinical Findings
Dyspnea, hypoxemia and bilateral pulmonary
edema. Other reported findings include hypotension,
tachycardia and fever (1-2°C rise from baseline).
Radiological Findings
Characteristic chest x-ray results show
bilateral patchy infiltrates, with alveolar and/
or interstitial patterns. The chest x-ray may
indicate non-cardiogenic pulmonary edema
without cardiac enlargement or other evidence
of fluid overload.
Blood Products Implicated in Causing TRALI
All blood products have been associated with
TRALI. Products with high plasma content such as
fresh frozen plasma, apheresis platelet concentrates
and whole blood have been associated with the
greatest risk.
Etiology
TRALI may be attributable to the presence of
anti-HLA and/ or anti-granulocyte antibodies in the
plasma of multiparous females or donors who have
received previous transfusions.

Pathogenesis
A “Two-Hit theory” has been proposed in the
pathogenesis of TRALI:
1. Antibodies to white blood cell antigens (HLA,
granulocyte and monocyte) present in the
donor’s plasma bind to the white cells of the
recipient which results in activation of
complement and neutrophils. The aggregation of
white cells within the lungs, and subsequent
adhesion to the capillary endothelium produce
endothelial damage, capillary leakage and the
development of pulmonary edema.
2. The clinical condition of the patient (e.g.
sepsis, trauma, etc) causes sequestration of
primed neutrophils in the activated pulmonary
endothelium. This results in endothelial damage,
capillary leakage and the subsequent
development of pulmonary edema. The twoevent theory may explain the development of
TRALI when there is no evidence of donor
HLA/HNA antibodies.
Treatment
Treatment of TRALI is supportive. Mild forms of
TRALI usually respond to supplemental oxygen
therapy. Severe forms require mechanical ventilation
and ICU support. There is no role for diuretics or
corticosteroids. The majority of patients recover
within 72 to 96 hours. However, some patients are
slower to recover and may remain hypoxic with
persistent pulmonary infiltrates up to seven days.
Approximately five to ten per cent of cases are fatal
in spite of aggressive supportive care.
Importance of Diagnosing and Reporting TRALI
Transfusion-related acute lung injury (TRALI) is
a rare but potentially fatal complication of blood
product transfusion. The diagnosis and reporting
of TRALI will allow better understanding of the
incidence, clinical course and associated mortality
of this reaction. Furthermore, by identifying cases of
TRALI, steps can be taken to prevent further cases
of TRALI by investigating donors involved in these
cases and deferring them from further donations if
they are found to be implicated.
7
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Detection of Partial “D”Antigen or “D Variant”
Huma Warsi
Haematology

D antigen is a protein with many parts, found
on the surface of red blood cells. The D antigen
is also known as the “Rh factor” and it tells us
blood type. People are either D (Rh) negative or
D (Rh) positive. The D antigen may show up only
weakly. Red blood cells from these people are
also Du positive.
Weak D (DU) red cells have historically been
defined as having a reduced amount of D antigen,
requiring an indirect Antiglobulin test (IAT) for
detection. The number of samples classified as
weak D however, depends on the characteristics
of the typing reagents, which have changed over
the years. Weak D expression results primarily
from single nucleotide mutations in RHD that
encode amino acid changes predicted to be
located intracellularly, or in the trans membrane
regions of red blood cell rather than on the outer
surface of the red cell.The mutations affect
insertion of the protein in the membrane,reflected
in the reduced number of D antigen sites on the
red cells.
Parial D red cells have historically been classified
as D positive. These red cells were predicted to
be missing portions of D and indeed the majority
of partial D phenotypes is due to hybrid genes
in which portions of RHD are replaced by the

8

corresponding portions of RHCE. The novel
sequences of the hybrid Protein resulting from
regions of red joined to RhCE not only can result
in the loss of D epitopes but also can generate
new antigens.

Source: Bloodblood journal. hematology library Vol 89 no 51779-1786

Clinical Significance During Pregnancy
Mothers who are “partial D” should be considered
D (Rh) negative. These mothers could build up
antibodies to the part of the “D” antigen they lack.
If their baby is D (Rh) positive, the antibodies
could destroy the baby’s red blood cells. This leads
to hemolytic disease of the fetus and newborn, or
“HDFN.” These mothers will need treatment during
pregnancy to prevent HDFN.
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Monoclonal Gammopathy of Undetermined
Significance (MGUS)
Dr Muhammad Shariq Shaikh
Haematology

Monoclonal gammopathy of undetermined
significance (MGUS) is defined as the presence
in the serum of an M-protein <30 g/L, bone
marrow clonal plasma cells <10 per cent, no
end organ damage (CRAB: hypercalcemia, renal
insufficiency, anaemia, bone lesions) and no
evidence of B-cell lymphoma or other disease
known to produce an M-protein. Paraprotein or
M-protein refers to existence in blood of a single
homogeneous (monoclonal) immunoglobulin
typically secreted by expanded clone of terminally
differentiated B cells.
MGUS is an asymptomatic condition and
is usually discovered unexpectedly. Typical
laboratory and radiographic abnormalities are
absent. Its prevalence is approximately three per
cent in persons over age 50 which increases to
more than five per cent beyond 70 years of age.
It is more common in man (M:F 1.5:1) and more
than twice as frequent in African Americans
as in Caucasians. Common associations
include connective tissue disorders, peripheral
neuropathies, dermatological, endocrine and liver
diseases. It may often be seen as a transient event
following solid organ and bone marrow stem cell
transplantation.
Approximately 70 per cent are IgG, 15 per
cent IgM., 12 per cent IgA and three per
cent are biclonal1. MGUS may consist of
immunoglobulin light chain only in up to 20
per cent and is only detected by serum free
light chain assay. Bone marrow aspirate and
trephine does not contribute to the diagnosis
as plasma cells are not markedly increased.
Immunophenotyping by flow cytometry however,
frequently shows two populations of plasma
cells, one with a normal immunophenotype
(CD38 bright+, CD19+ CD56-) that is polyclonal

and a monoclonal population with an aberrant
phenotype, most often either CD19-/CD56+ or
CD19-/CD56-.
Although the prevalence may differ, abnormal
karyotypes when present in MGUS are the
same as those found in myeloma. Translocation
involving immunoglobulin heavy chain (14q32)
gene are detected in nearly 50 per cent of
the cases with t( 11;14) (q23:q32) being the
commonest translocation (15-25 per cent).
Deletions of 13q are detected in 40-50 per cent
cases however, its relation to progression of
MGUS are not clear. Activating K- and NRAS
mutations are much less frequent in MGUS (-5
per cent) compared to myeloma (30-40 per cent).
Although genetic alterations and gene expression
patterns probably can distinguish advanced
myeloma from MGUS there are no unequivocal
intrinsic differences that distinguish MGUS from
myeloma.
M-protein levels remain stable with no other
evidence of progression in most individuals.
However, evolution to an overt plasma
cell myeloma, amyloidosis, Waldenstrom’s
macroglobulinemia and other lymphoproliferative
disorder may occur at a risk of one per cent per
year. Factors associated with increased likelihood
of progression include higher M-protein level
(>4 times with level of 25g/L to that of <5g/L),
IgM or IgA MGUS, fraction of plasma cells in
bone marrow with abnormal phenotype, DNA
aneuploidy and subnormal levels of polyclonal
immunoglobulins.
Thus, MGUS should be considered a preneoplastic condition and patients should be
appropriately counseled and followed by
monitoring M-protein levels.
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Understanding Six Sigma Methodology
Lena Jafri and Saba Azeem
Chemical Pathology

Six Sigma is a statistical measure of quality for
process improvement originally developed by
Motorola in 1985. It is a metric that quantifies the
performance of processes as a rate of Defects Per
Million Opportunities (DPM, or DPMO). A Six
Sigma-capable process has so little random variation

Table 1. Sigma Levels and Defects Per Million of Opportunities

Sigma Level DPMO Error Free Rate
Six Sigma

3.4

99.9997%

Five Sigma

233

99.977%

Four Sigma

6210

99.4%

Three Sigma 66810

93%

Two Sigma

308500 69%

One Sigma

691500 31%

that the standard deviation, when multiplied by six,
gives a quantity that meets the customer requirement
for that process. It sets a quantitative goal for process
performance and in turn quality improvement. It was
in March 1998 that Six Sigma was applied to the
healthcare industry for the first time. The delivery of
healthcare demands the highest level of quality and
the most advanced quality management system.
A Six Sigma process is one in which 99.9997 per

Table 2. Tools to Dry Sig Sigma Projects

better performance and vice versa. Quality is
assessed on the sigma scale with a criterion of three
sigma as the minimum allowable sigma for routine
performance and a sigma of 6 being the goal for
world-class quality.
Six Sigma projects follow two project methodologies
with acronyms DMAIC and DMADV. Each
methodology is composed of five phases. (Table
2) To improve an existing process the DMAIC
methodology is used and to implement a new process
or product DMADV is used.
There are several key players involved in
launching a Six Sigma project. Prior to starting
a project, a multidisciplinary team is formed.
Similar to martial arts system formal Six Sigma
programs adopt a ranking terminology. For
example ‘Black Belts’ and ‘Green Belts’, which
denote people with different levels of expertise
(and certification). Six Sigma ‘Black Belts’ use
a vast array of tools at each stage of Six Sigma
implementation to control variation in process
quality, and to manage teams and communication.
This helps in creating an infrastructure within the
organization.
A major difference between Six Sigma and other
quality programs is that Six Sigma incorporates a

DMAIC

DMADV

Define: process of interest that needs to be improved

Define: goals as per customer demands and
satisfaction

Measure: relevant data, measure performance

Measure: production capabilities and risks

Analyze: what is affecting our processes

Analyze: to develop alternatives

Improve/Innovate: redefine the process, remove
cause, brain storming needed

Design: an improved alternative

Control: documentation of new process and training,
monitor the process

Verify: run pilot run to verify design

cent of the products manufactured are statistically
expected to be free of defects or errors (3.4 defects
per million). (Table 1) Higher sigma values indicate
10

control phase with ongoing checks. This ensured
that once improvement is achieved it is not
temporary but is maintained over time. Six Sigma
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methodologies are well suited for application
to laboratory settings because of the inherent
need for statistical precision and quality control in
laboratory testing, as well as the highly repetitive
nature of laboratory work. It can serve as a quality
indicator for pre-analytical, analytical and post
analytical processes. Six Sigma values can be
calculated for quantitative assays (total allowable
error – bias / CV), for internal quality control
data and also in proficiency testing. The Clinical
Laboratory Improvement Amendments of 1988
and the Joint Commission on Accreditation of
Healthcare Organizations requires laboratories to
perform external comparison of their performance
with others in a process commonly known as
benchmarking. The data of Six Sigma studies and
projects is evolving and it can become the tool for
benchmarking and to compare laboratory error
rates with peers.
Example
To better understand the calculations involved in
sigma metrics here is an example from laboratory
practice. A process improvement initiative using
Six Sigma strategies between May to October 2013
was taken at the Section of Chemical Pathology,
Department of Pathology and Microbiology, Aga
Khan University Hospital (AKUH) to reduce the
STAT tests turnaround time in emergency department
(ED) laboratory. A team led by pathologist and
comprising of two senior technologists conducted
the project using ‘Define Measure Analyze Improve
Control’ (DMAIC) methodology. Review of total
STAT data showed that 0.25 per cent STAT tests
were not reported in one hour, which is the cutoff
reporting time of Clinical Laboratory of AKUH.
In the commencement of the project the problem
was defined as average STAT delay of 14 out of six
thousand samples per month (DMAIC).
The approach adopted was direct observation
and process analysis. Tests that exceeded
one hour goal required for completion was
considered a delay. The base line delay using

VOL. 40, ISSUE 1

Six Sigma calculator was 4.33 on sigma scale
(DMAIC). A group member was assigned to
daily monitor and records the process flow of
STAT delays along with the reason for the delay.
Group met fortnightly and brain storming was
done, corrective and preventive actions for each
delay were taken (DMAIC). Root cause analysis
identified delay in processing of specimens,
instrument malfunctioning and their late
rectification and interruption in data transmission
through instrument to central information system.
Frequency of delays was more in night shifts.
Significant time was taken in sample processing
because of inadequate staffing. and in answering
phone calls by technologists during busy periods.
On spot feedback mechanism after the delays did
not exist (DMAIC). On the basis of root cause
analysis technologists were educated about the
importance of STAT test in patient care. Proper
maintenance of instrument by evening staff was
ensured to give support to night shift. A new
backup instrument with short throughput was
arranged. Brief ED laboratory visit by senior
technologist was arranged on daily basis to deal
with staffing challenges, equipment problems,
quality issues, and staff acknowledgments and
feedbacks (DMAIC). Process of sample analysis
from the time of sample receiving till sign out was
revisited and a detailed workflow diagram was
created and made available on the soft board for
the technologists (DMAIC).To improve informing
the results of STAT tests with panic value a
voice pager system was also introduced in the ED
(DMAIC). On reanalysis of the number of STAT
delays it was noted that it reduced from 4.33 to
5.01 on sigma scale. Impact of project was that
STAT tests entries are now done on fast track.
Applying Six Sigma methodologies in healthcare
helps in improving issues of non-compliance
and enhancing effectiveness in laboratory
staff. Importance of Six Sigma in laboratory
is gradually increasing and is a tool by which
clinical laboratories can improve their processes
and achieve their quality goals.
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Blood Collection for Culture
Dr Naima Fasih
Microbiology

Purpose(s)
To ensure provision of safe, timely and convenient
process for the patients undergoing of blood
specimen collection.
Responsibility
All assigned consultants, registered nurses, assigned
nursing staff, laboratory personnel and unit
receptionist.
Equipment
Culture bottles (Two for adults and one for peads)
Skin disinfectant
Option 1: Sterile alcohol swab and two per cent
chlorhexidine glauconate in 70 per cent isopropyl
alcohol impregnated swab
Option 2: Sterile alcohol swab and 10 per cent
povidine iodine
Option 3: Sterile alcohol swab (only for <2 months
children of age)
Clean Gloves
Syringe 10 ml (02)
Patient Identification sticker
Alcohol wipes to disinfect bottle septum
Tourniquet

Figure 1. Culture Bottle

Procedure
Apply tourniquet to the extremity and identify the
puncture/ phlebotomy site.
Preparation of the phlebotomy site.
Step 1: Vigorously cleanse the skin over the
venipuncture site with 70 per cent isopropyl or ethyl
alcohol to remove surface dirt and oils. Allow to dry.
(see Figure 2)

Procedure
Preparatory Phase
Explain procedure to patient/family.
Verify the patient’s identification by checking the
patient name and identification number.
Wash or sanitize hands and wear latex gloves.
Follow Standard Precautions for all patients.
Assemble necessary equipment before preparation of
the patient’s skin.
Check the expiry of the culture bottle.
Adult: Two bottles (One aerobic + One anaerobic)
Children: One bottle (paediatric)
Remove the cap from culture bottles. Clean septum
with (sterile) alcohol wipe (do not use iodine as it
damages the septum). Allow it to dry.
(see Figure 1)
12

Figure 2. Clean the sking over the venipuncture

Step 2: Disinfect a five centimeter area in concentric
circles (see Figure 3), moving outward from
center of the site using two per cent chlorhexidine
glauconate in 70 per cent isopropyl alcohol
(impregnated swab) or 10 per cent povidine iodine.
Step 3: Leave the disinfectant to act for 60 seconds
before venipuncture.
Step 4: Clean patient’s skin again with alcohol swab.

VOL. 40, ISSUE 1

APRIL 2014

Children: 1ml/year of age
Order of Inoculating Blood Culture Bottles

Figure 3. Disinfect Area

DO NOT touch the venipuncture site after
preparation and prior to phlebotomy.
Appropriate amount of Blood for Culture Draw
Adult: 10 ml blood per culture bottle is
recommended.

Inoculate the aerobic bottle first followed by the
anaerobic bottle.
Do not change needle during transferring of blood
from one bottle to other.
If an inadequate amount of blood was obtained
(less than 5 cc), and repeat phlebotomy cannot
be performed; all blood should be preferentially
inoculated in the aerobic culture bottle.
Transport to Laboratory
As soon as possible.
In case of delay bottle should be kept at room
temperature for 4hours.
Inoculated blood culture bottle will never freeze or
refrigerate.

Inadequacies of Salmonella Serology for
Diagnosing Enteric Fever
Dr Joveria Farooqi
Microbiology

Enteric fever is a systemic infection with
typhoidalSalmonella species, including Salmonella
Typhi, S. Paratyphi A, B and C, which are
transmitted through feco-oral route. The burden of
typhoid and paratyphoid fever is highest in South
Asia compared to the rest of the world especially
in adolescents and children. Annual incidence of
typhoid fever is around 250 to 500 per 100,000
child-years in low socioeconomic communities
of Karachi. The diagnosis is suspected on fever
of more than three days duration, sore throat and
abdominal pain. These are all nonspecific symptoms
and could occur in other endemic infections, like
malaria and dengue.
Traditionally the definitive diagnosis of enteric fever
is by isolation of Salmonella Typhi or S. Paratyphi A,
B or Cfrom blood, stool and bone marrow cultures.
The sensitivity of blood culture ranges from 50
per cent to 80 per cent with a specificity of 100 per
cent. Sensitivity of blood cultures in diagnosing
typhoid fever in many parts of the developing
world is further limited because of prior antibiotics.

Although bone marrow cultures may increase the
likelihood of bacteriologic confirmation of typhoid,
these are difficult to obtain and relatively invasive.
The greatest advantage of culture-based diagnosis
is availability of susceptibility profile of the isolate.
This can direct physician to prescribe appropriate
antibiotic therapy ensuring cure and eradication, thus
reducing transmission.
Detection of raised titers of agglutinating serum
antibodies against the lipopolysaccharide (LPS) (O)
or flagellum (H) antigens of serotype Typhi (the
Widal test) has been in use for a long time.The Widal
test is easy, inexpensive, and relatively noninvasive.
It can be of diagnostic value when blood cultures
are not available or practical. The results must be
interpreted cautiously because of the low sensitivity
of the test. The serologic diagnosis of typhoid is
also fraught with problems because results of a
single Widal test may be positive in only 50 per
cent of cases in endemic areas, and serial tests may
be required in cases presenting in the first week of
illness.
13
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Detection of specific antibodies to typhoidal
Salmonellae (Typhi dot) is also used as supportive
tests for typhoid diagnosis. Rapid salmonella
serological tests, which detect IgM and IgG
antibodies to a Salmonella typhi-specific outer
membrane protein, were considered sensitive and
specific for the diagnosis of enteric fever when
they were first introduced. Serological diagnosis
has its own limitations. Initial studies showing high
sensitivities were hopeful because of the chance of
detecting typhoid earlier. It soon became evident
that high sensitivity meant large number of false
positive results; implying 10-15 days of unnecessary
antibiotic therapy administered to patients without
enteric fever. Antibodies against other gram-negative
bacteria, like E. colifrom urinary infection and nontyphoidal Salmonella species causing diarrhoea;
viruses, e.g. dengue; and even malaria can cross-

react with the Salmonella-OMP in the kit, thus giving
rise to false positive results.
False negative results are also a problem when
the test is performed in the first week of infection.
Sensitivity (40-77 per cent) and specificity (80-95
per cent) of serological tests for enteric fever is
inadequate for clinical diagnosis considering its
high prevalence in Pakistan. Therefore, experts
recommend that these serological tests should not
be used for diagnosis of enteric fever, except as
evidence of past infection.

Detection of Salmonella DNA in blood and urine
through nested or multiplex PCR have yielded
hopeful results, but it is still not established as a
diagnostic method for enteric fever. There is a need
for more efficient rapid diagnostic test for typhoid
especially during the acute stage of the
CURRENT DIAGNOSIS
disease. Until then, culture remains the
method of choice and it becomes even
l
In the absence of localizing signs, the early stage of the 		
more important to curtail the use of
disease may be difficult to differentiate from other endemic
antibiotics before blood cultures are sent.
diseases such as malaria or dengue fever.
l

The presentation and diagnosis of typhoid fever may be
tempered by coexisting morbidities and early administration
of antibiotics.

l

The presentation of typhoid may be more dramatic in children
younger than 5 years of age, with comparatively higher rates
of complications and hospitalization.

l

The sensitivity of blood cultures in diagnosing typhoid fever
may be limited in many developing countries because of
antibiotic prescribing.

l

Multidrug-resistant (MDR) typhoid is a more severe clinical
illness with higher rates of toxicity and complications. In
particular, recent cases of quinolone-resistant typhoid may be
more severe.

In view of this evidence recent
recommendations based on high quality
data from studies conducted in endemic
areas strongly discourage the use of
such tests for enteric fever.Thus, in
keeping with international evidencebased recommendations, the Aga
Khan University Clinical Laboratories
will shortly discontinue rapid typhoid
serological test.
For diagnosis of typhoid fever, blood,
stool and bone marrow cultures are gold
standard, and are advised in suspected
cases.

Routine Screening for Macroprolactin in
Hyperprolactemic Sera
Dr Noreen Sherazi
Chemical Pathology

It is well established that prolactin occurs mainly
in three molecular forms: a monomeric prolactin
with molecular weight ~ 23 kDa; a larger form
named “big prolactin” (~50 kDa) and a “big, big
14

prolactin” with a molecular weight over 100 kDa
which is also called macroprolactin (MaPRL). In the
majority of cases, MaPRL consists of monomeric
prolactin connected with immunoglobulin; most
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frequently type G. The predominant isoform
of prolactin in healthy people, and also in most
individuals with hyperprolactinemia, is a monomeric
molecule which amounts to more than 85 per cent of
circulating hormone. However, in some patients with
hyperprolactinemia, the dominant form becomes
MaPRL, which in normal conditions does not exceed
two per cent of total serum prolactin.
MaPRL is biologically inactive because the large
molecular size of this complex prevents its crossing
through the capillary blood barrier and reaching
target cells. The percentage of hyperprolactinaemic
patients with macroprolactinaemia have been
studied several times, and ranges from 10 per cent
to 45 per cent in literature. Among methods used
to detect MaPRL, gel filtration chromatography is
acknowledged to be the gold standard, but it is highly
complex, time-consuming, and expensive procedure
prohibits its use in routine screening for MaPRL.
The polyethylene glycol precipitation test is widely
used to detect pseudohyperprolactinemia caused by
MaPRL. Current best practice recommends that all
sera with increased total prolactin concentrations be
sub fractionated by PEG precipitation to measure
the bioactive monomeric prolactin concentration,
a more clinically meaningful variable. Sub

fractionation with PEG allows laboratories to
distinguish patients with true hyperprolactinemia, in
which there are supraphysiological concentrations
of bioactive monomeric prolactin, from those
with macroprolactinemia, which is characterized
by increased concentrations of MaPRL together
with normal concentrations of bioactive
monomeric prolactin. In the absence of PEG
screening, misdiagnosis and consequent clinical
mismanagement along with financial burden on
patients with hyperprolactinemia can occur.
We at the Section of Chemical Pathology,
Department of Pathology and Microbiology,
Aga Khan University Hospital in the interests of
clarity and good laboratory practice, have recently
started routine screening of MaPRL in specimens
having high total prolactin levels (i.e. above the
reference interval till 200 ng/ml). Gel tube with
5-7 cc of clotted blood or serum is required. We
will report results as absolute monomeric prolactin
concentration, together with an appropriate reference
interval i.e. males 3.6 – 12.4 ng/ml and females 4
– 18.5 ng/ml. This will have overall clinical impact
on diagnosis, management and cost effectiveness
proving to be a beneficial quality improvement
initiative.

Molecular Analysis of Alpha Thalassaemia by
Multiple Ligation Probe Assay
Azra Samreen and Dr Zeeshan Ansar Ahmed
Molecular Pathology

Introduction
The Alpha thalassaemia is an inherited disorder of α
globin gene, which encompasses all those conditions
in which deficit production of α globin chain of
hemoglobin (Hb) occurs. Due to underproduction
of α globin chain, γ and β globin chain synthesis is
excessively increased to compensate during fetal and
adult life.
Individuals having mutation in one allele of α globin
gene on chromosome 16 are said to have
α thalassaemia trait, they may be associated
with mild anemia or with normal hemoglobin.
Compound heterozygotes and some homozygotes
for α-thalassaemia have moderately severe anemia

characterized by presence of HbH disease. In
neonatal period some individual who make very little
or no alpha globin chains have a very severe form of
anemia which, if untreated, causes death called the
Hb Bart’s hydrops foetalis syndrome.
Genetics of Alpha Globin
Alpha globin gene is located on chromosome 16
(16p 13.3) whereas beta globin gene resides on
chromosome 11 (11p 15.4). There are two functional
α genes present on each chromosome 16.The size
of the cluster gene is 70 kb which consist of three
pseudo gene ψ, έ, ά2, and ά1 and four functional
genes, έ, ά2, ά1 and φ. α gene carry three exon and
two introns. While, 10 variable number of tandem
15
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repeats are located around α globin gene locus. Two
α genes lie adjacent to each other. As each diploid
cell contains two sets of each chromosome, hence
there are four alpha globin alleles are present in a
normal individual Figure 1.
Alpha Globin Gene Cluster
Chromosome 16
Zeta 2

Zeta 1

5’

Alpha 2

HbA1
Alpha 1

-

3’

Figure 1. Diagramatic representation of α globin gene on chromosome 16

Epidemiology
The prevalence of α thalassaemia is also like others
common globin gene disorder
(β thalassaemia and sickle cell trait). It demonstrates
high frequency throughout all the tropical and
subtropical region of the world. In some areas,
the carrier frequency of α- thalassaemia may be
as high as 80-90 per cent of the population. Of all
globin disorders, α- thalassaemia is the most widely
distributed and therefore many individuals in these
areas have interacting combinations of these variants
(e.g. both α and β thalassaemia). Due to differences
in the interactions between various molecular
defects underlying α- thalassaemia, HbH disease is
predominantly seen in South East Asia, the Middle
East and the Mediterranean. Similarly the Hb Bart’s
Hydrops foetalis syndrome is predominantly seen in
South East Asia.
Molecular Analysis
Due to advent of latest molecular tools, it has
becomes possible to accurately and rapidly diagnose

α- thalassaemia, while identify the precise defects
underlying these disorders. Ultimately, most α globin
chain rearrangements have been characterized by
MLPA and DNA sequence analysis. For suspected
but currently unknown rearrangements, Southern
blotting or MLPA analysis may be used. Southern
blot was the classical method to detect deletions
causing α-thalassaemia before new techniques
were introduced. Currently, MLPA is the method of
choice. It is based on ligation of multiple probe-pairs
hybridized across a large region of interest, followed
by semi-quantitative amplification using universal
tag PCR primers and subsequently fragments
analysis.
Method
MLPA is performed on DNA samples for analysis
alpha thalassamia. It can detect both deletion and
duplication of alpha globin gene. The protocol
consists of five steps spread on two days. MLPA test
for alpha thalassemia is offered by the Molecular
Pathology Section.
The steps are follows:
1. Hybridization reaction overnight incubation Day one
2. Ligation of probes – Day two
3. PCR amplification Day – two
4. Capillary Electrophoresis
5. Interpretation of data

Table 1. Different Types of Alpha Thalassaemia Based on Deletion Type Mutation

Genotypes

Description

Symptoms

αα/αα

Normal –All four α alleles are present Normal heamatological profile

-α/αα

Only one α allele absent
Genetically silent carrier

Clinically asymptomatic usually, diagnosed during
antenatal screening

-α/-α or --/αα Two α alleles are absent
Heterozygous or Homozygous trait

Mild hypochromic, microcytic anemia
(iron deficiency)

--/-α

Three α alleles are absent
HbH disease

Moderate anemia, jaundice and
Hepato- splenomegaly
(folate deficiency)

--/--

Totally absent α chain
Hydrops fetalis

Intrauterine death, skeletal deformities, cardiovascular
problems, growth retarded

16
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Table 2. Alpha-Thalassaemia Mutations in Different Ethnic Groups

Ethnic Group
India

Type of Thalassaemia
α+

Mutation(s)

Occurrence

- α3.7

Common

- α4.2

Less common

α Koya Dora α

Relatively rare

α IVS I-117 α

Relatively rare

α+ - α0

α PA3(AATA- -)

Also found in Hindustani from Surinam

Middle East

α0
α+
α+ - α0

- - MED 1
- α3.7
α PA1(AATAAG)

Common in Iran, Palestinians, Arab
population
Common in Iran, Palestinians, Arab
population
Relatively common in Arab population

South-East Asia

α0

- - SEA

Most common deletion among Asians

- - FIL

world wide

- -THAI

Mainly in Philippinians
Common among Thai

- α3.7

Relatively common

- α4.2

Relatively rare

α Constant Spring

One of the most common non-deletion

α Suan Dok

variants in Chinese

α Quong Sze

Highly unstable α-chain

α Pakse

Highly unstable α-chain

α init A-G

Highly unstable α-chain, found in Thai,

α init -TG

Laotian

α+

Common in Vietnam
Common in South-East Asia
Source: Adapted from Barbara J. Bain, Haemoglobinopathy Diagnosis 2nd edition 2006 {Bain, 2006126/id}
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Prognostification of Acute Myeloid Leukemia
with FLT 3 Mutation
Madiha Salahuddin & Dr Zeeshan Ansar Ahmed
Molecular Pathology

Introduction

Structure and physiological role in haemopoiesis
FLT3 gene located on chromosome 13 (13q12);
it is comprised of 24 exons extending over
more than 100 kilobases. FLT3 shares the
structural features of the other members of
its subfamily, namely five immunoglobulinlike domains in extracellular region, a single
transmembrane sequence, and, intracellularly,
a short juxtamembrane portion followed by the
interrupted kinase domain. FLT3 is expressed
in virtually expressed in every tissue thus far
examined. In human hematopoietic cells, FLT3
expression is restricted to the CD34-positive
fraction of bone marrow and a smaller fraction
of CD34-negative cells destined to become
dendritic cells. Its activation send message
to biochemical pathways that promote cell
growth and inhibit apoptosis during normal
haemopoiesis.

Acute myeloid leukemia (AML) is a severe
progressive malignancy that generally has short
survival because of heterogenetic origin, less
responsive to treatment and tendency to early
relapse. Abnormal activity of receptor tyrosine
kinase has long been the main pathogenic finding
in leukomogenesis, such as mutant forms of KIT,
ABL, and platelet-derived growth factor receptor
(PDGF-R) are among the constitutively activated
tyrosine kinases that have been identified.
FMS-like tyrosine kinase-3 (FLT3) is a member of
the PDGF-R subfamily of receptor tyrosine kinases,
which was originally identified by its expression
in hematopoietic stem/progenitor cells, and its
importance in normal lymphohematopoietic stem
cell function is now well established.

Pattern seen on agarose gel
Diagnosis

Relapse

LOH
ITD/-

ITD/-

ITD
Wt

expansion

“early”
ITD mutation

ITD/Wt
ITD/Wt
“late”
ITD mutation

Wt/Wt

+++

++
expansion

ITD/Wt

++

Wt/Wt

ITD/WT

expansion

ITD/Wt

ITD
Wt

ITD
Wt

Wt/Wt
mutation (s)
Normal stem cell

Leukemia progenitor cells

Wt/Wt

Self-renewing
Figure 1. A model explaining the loss of some FLT3/ITD mutations at relapse
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Biological Consequences of Abnormal FLT3
Activation
Molecularly, mutation-activated FLT3 induces
transformation in immature clonal neoplastic (Blast)
cells Figure 1. These cell completely blocks G-CSFinduced differentiation and suppresses the expression
of myeloid transcription factors the profound
biochemical consequences of its constitutive
activation. FLT3 mutations have also been seen in
myelodysplastic syndrome (MDS) in about 3-5 per
cent of newly diagnosed patients. In MDS patients
without FLT3 mutations, they sometimes appear
when these patients progress to AML.

FLT3. A number of FLT3 activating mutations
have been found in leukemia patients; the first of
these to be identified was the FLT3/ITD mutation.
Subsequent to this an activating point mutations at
aspartate 835 (or isoleucine 836) in the activation
loop of the FLT3 kinase domain was discovered.
Both types of mutations are primarily found in
AML. Patients with this abnormality were found
to have an increased incidence of leukocytosis
and a decreased overall survival (OS) when
compared with patients without FLT3/ITD
mutations. Numerous groups around the world
have now confirmed and extended these findings
in both adult and pediatric AML.

Significance of FLT3 in Leukemia

Method for FLT3 Detection

Expression of FLT3 has been identified in
several types of leukemia and lymphoma. In
addition, FLT3 expression was demonstrated
in most pre-B cell, myeloid, and monocytic
leukemia. Recently, it was discovered that FLT3
is universally expressed in primary AML blasts.
Moreover, FLT3 mutations at diagnosis have been
found to be occasionally acquired at the time of
relapse. In other types, a lesser portion of chronic
myelogenous leukemia (CML) blast crisis, as
well as chronic lymphocytic leukemia (CLL) and
even T-cell ALL cells have been shown to express

DNA is extracted by Qiagen Blood DNA isolation
kit, from fresh bone marrow or peripheral blood.
Extracted DNA is then subjected to amplification
using ITD primers and also with D835 primers
in separate PCR reactions. Amplified products
for D835 mutation are digested with restriction
enzyme EcoRV. Gel electrophoresis is performed
to analyze amplification and EcoRV digested
products Figure 2. This test is being offered by
the Molecular Pathology section, Department
of Pathology and Microbiology, Clinical
laboratories, AKUH.

Figure 2. (A) Showing PCR products of FLT3 ITD & D835 on ethidium bromide stained-agarose gel
(B) Showing EcoRV digested products of FLT3 D835 on ethidium bromide-stained agarose gel
Source: M Levis1 and D Small, FLT3: IT Does matter in leukemia; Leukemia (2003) 17, 1738–1752.
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Interferon Gamma Release Assay (IGRA)
for Detection of Mycobacterium tuberculosis
Infection in the Host
Maheen Hassan, Zahida Amin & Madiha Salahuddin
Molecular Pathology

Background

species of the Mtb complex, such as M. bovis
BCG. The QFT assay has two stages; firstly, it
involves incubation of whole blood with TBspecific antigen, control antigen (mitogen) and
nil control. The TB antigen tube assesses the
IFN-γ response to highly specific TB antigen, the
negative control tube adjusts for background noise
and the positive control tube (Mitogen) indicates
the effectiveness of T-cell mediated responses in
the patient. Secondly, plasma is harvested from
tubes and IFN-γ level is determined by an enzyme
linked immunoabsorbent assay (ELISA).

Tuberculosis (TB) is the leading cause of death
and a major cause of morbidity worldwide.
Pakistan ranks sixth globally, among the 22 high
TB burden countries, according to the World
Health Organization (WHO). It is estimated that
one third of the world’s population is latently
infected with Mycobacterium tuberculosis
(Mtb). However, only a small proportion of
these progress to active disease. Traditionally,
exposure to Mtb has been assessed with the
use of a tuberculin skin test (TST)
or Mantoux test. In a TST reaction,
Antigen
IFN-γ
purified Mycobacterial peptide
Presenting
Cell
(APC)
antigens are injected intra-dermally
into the skin and a delayed type
hypersensitivity response (DTH) to
the antigens is measured after 48 h
Antigen
by measuring induration at the site
Specific T
Cell
of peptide injection. While this gives
an indication of Mtb exposure in the
APC specific T
APC Processes
APC Presents
host, it does not discriminate between
cell produces
Antigen
Antigen to Antigen
Antigen
Mtb and other mycobacteria of the
specific T cell
IFN-γ
Mtb complex such as M. bovis BCG.
Figure 1. Principle of Mtb Interferon gamma release assay
Therefore, the TST reaction is affected
by BCG vaccination status of the host.
Interpretation of the QFT Assay
Principle of the Assay
The QFT is an indirect test for Mtb infection:
Test based on the principle that T-cells from a
T-cells reactive to Mtb specific antigens are only
whole blood sample, when exposed and incubated
present in those infected with Mtb. Results are
with a specific Mtb antigen, will produce
interpreted (as shown in Table 1). A test for Mtb
interferon-gamma (IFN-γ) in an individual who
is considered positive if the amount of IFN-γ in
has been infected with Mtb (Figure 1). An IFN-γ
response to TB antigen (minus Nil) is >=0.35
release assay, commonly known as IGRA is one
International Units (IU)/ml.
in which IFN-γ released by T cells in response
to exposure to Mtb antigens is measured. The
Utility of the Assay
Quantiferon TB Gold In-Tube (QFT) is a whole
blood based IGRA that measures the cellThe QFT - IGRA is intended for use as a
mediated immune response (IFN-γ) response
diagnostic aid for Mtb infection, whether active
to three specific proteins, ESAT-6, CFP-10 and
tuberculosis disease or latent TB infection (LTBI),
TB7.7 which are found in Mtb but not in other
and is intended for use in conjunction with risk
20
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Table 1. Interpretation of IGRA – QFT Assay Results

Interpretation

Nil*

TB Responset

Mitogen Responset

Positive

<8.0

>0.35 IU/ml and >25% of Nil Any

Negative**

<8.0

<0.35 IU/ml or <25% of Nil

>0.5

Indeterminate++ <8.0

<0.35 IU/ml or <25% of Nil

<0.5

Any

Any

>8.0

* The interferon gamma (IFN-γ ) concentration in plasma from blood incubated without antigen.

+ The IFN-γ concentration in plasma from blood stimulated with a single cocktail of peptides representing early
secretory antigenic target-6 (EAST-6), culture filtrate protein-10 (CFP-10), and part of TB 7.7 minus Nil.
$ The IFN-γ concentration in plasma from blood stimulated with mitogen minus Nil.
Interpretation indicating that Mycobacterium tuberculosis infection is likely.
** Interpretation indicating that M. tuberculosis infection is not likely.
++ Interpretation indicating an uncertain likelihood of M. tuberculosis infection.

assessment, radiography and other medical and
diagnostic findings. It is useful for detection of
Mtb in patients where differential diagnosis of
this infection may lead to a change in treatment
and management of the case. This is a qualitative
test. The IFN-γ response to TB antigen should not
be used to monitor disease progression. A QFT-G
Positive result cannot distinguish between latent
and active TB.
The advantage of this test is that specific antigens
to Mtb are used and one patient visit is required. In
contrast to TST, it is unaffected by BCG vaccine.
Individuals who are on anti-inflammatory drug
treatment such as tumor necrosis alpha (TNF-α)
inhibitors for rheumatoid arthritis may be at risk
of developing TB if they already have latent TB.
In such cases, QFT may be useful assessing Mtb

infection in rheumatic disease patients receiving
immunosuppressive therapy.
The disadvantage is that QFT is an expensive test
and requires laboratory expertise. A factor which
limits the efficacy of the QFT test is the cell
mediated immune response in the host. Therefore,
if immunity is compromised in the patient and T
cell responses are diminished such as in patients
with human immunodeficiency virus (HIV)
infection, or those with oncological disorders,
the QFT may give inaccurate results. However,
QFT is more sensitive and specific then the TST
for detecting tuberculosis infection in HIV +ve
individuals. In children, the utility of QFT is
still unclear as in young children cell mediated
immune responses are not fully developed and
this may result in false negative results.
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An Analysis of Needle Stick Injury in the
Department of Radiology
Amin Rajani and Raza Sayani
Department of Radiology

Needle stick injury is a global issue
OTHER.
2
and a major threat to health care
RETRIEVING NEEDLE FROM BIOPSY GUN
2 CAUSES
workers. Occupational exposures to
percutaneous injuries are a substantial
HANDLING LINEN
2
source of infections with blood borne POST PROC. CLEANING / HANDLING SHARPS
6
pathogens such as hepatitis B virus,
PATIENT HANDLING ON BED
3
(HBV), hepatitis C virus, (HCV) or
DISPOSING / HANDLING SHARP BIN
4
Human immunodeficiency virus,
(HIV) among health-care workers.
6
DURING US INTERVENTION
NSI’s are generally under reported
DURING FLUORO PROCEDURE
4
and data regarding them are usually
DURING VIR PROCEDURE
		8
sparse, especially in developing
RECAPING
5
countries like Pakistan. Obtaining
accurate figures for the incidence
CANNULATION
		
13
of needle stick injuries is very
0
2
4
6
8
10
12
14
difficult. Its frequency in Radiology
Department is generally considered Figure 2: causes of needle stick injuries
low as compared to surgery; however
main cause identified was cannulation Figure 2.
the Radiology Department staff and doctors are no
However, many injuries occurred during disposing
exemption. The frequency is increasing with the
of the used needles. In majority of cases the patients
rise in interventional procedures in the department.
were not infected with any known blood borne
We carried out a cross sectional survey in our
infection.
department to identify the frequency by recording all
self-reported needle stick injury data of health care
Over the years at institutions level as well
workers of the department.
as departmental level, we have regularly
emphasized the importance of infection control
In the last decade (year 2000-2010), 55 health
and NSI particularly. Additionally, faculty as
workers reported NSI. Radiographers and radiology
well as residents who are inducted, go through
residents received maximum injuries Figure 1. The
sessions and training for intervention procedures
HOUSE KEEPING
where they are taught measures to be taken
2%
when such an event occurs. Similar sessions are
NURSE
conducted for Technologists and Nursing staff as
14%
RESIDENTS
well.
22%
OJT
4%

PORTER
5%

RADIOLOGIST
18%
RADIOGRAPHER
35%
Figure 1: Percentage of house staff with needle stick injuries
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Timely surveillance is performed if a needle
stick injury does occur. However, the best
measure is prevention which can only be done
by repeated re-enforcements through various
techniques e.g. flyers, videos and lectures.
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Meeting Report: The 37th Annual Conference of
the Pakistan Association of Pathologists and The
2nd Joint Conference of the Societies of Pathology
Sibtain Ahmed
Chemical Pathology

The 37th Annual Conference of the Pakistan
Association of Pathologists / 2nd Joint Conference
of the Societies of Pathology was held in the
‘Mughal City of Gardens’ Lahore from December
20th to 22nd, 2013. The theme of the conference
was “Young Pathologists – Our Future.” In order to
maximize participation of young pathologists, the
organizing committee had arranged scholarships
for 100 young pathologists including residents and
technologists from across the country to attend the
conference. Scholarship consisted of travel expenses,
accommodation and registration fee.

Second day December 21, 2013 started with ‘meet
the experts’ session, a great learning opportunity
for maturing pathologists to acquire knowledge
from senior professionals in their respective
fields. It was followed by free paper sessions in
the different disciplines of pathology. A general
body meeting was also held during the day.
Several selected abstracts were also displayed
as posters which portrayed research advances
in the field of pathology. After the sunset the
exhausting day was masked by a shopping trip
and a wonderful dinner in the surroundings of the
famous Gaddafi Stadium.
On the third day of the conference two scientific
sessions were held. The conference closing
ceremony was held in afternoon and best oral and
poster presentations were announced.

Dr Shahid Pervez, Professor and Consultant Histopathology,
Aga Khan University Hospital, Karachi delivering a talk at the conference

The first day began with inauguration ceremony
on 20th December. This was followed by the “Razi
lecture”, by Dr. Mohammad Akhtar from King Faisal
Specialist Hospital Riyadh Kingdom of Saudi Arabia
on ‘Breast Cancer’ and impact of new diagnostics
including molecular modalities in breast cancer
diagnosis were highlighted. It was followed by
scientific sessions in which young scientists were
given a chance to present researches and studies they
have conducted in their respective disciplines. A
plenary session was also organized in which senior
Pathologists delivered talks on various aspects of
Pathology and Laboratory Medicine. In the evening
organizers had planned a get together at the famous
food street. A blend of rich cultural heritage and
delicious food was a refreshing experience towards
the end of a busy day.

Workshops of Histopathology, Hematology,
Microbiology, Chemical Pathology and Immunology
were also arranged and were facilitated by renowned
experts in the different disciplines of Pathology
respectively. The conference not only excelled in
presenting exciting developments in the field of
pathology and laboratory medicine, it provided
an excellent platform in bringing together the
future pathologist and the giants from the different
disciplines of pathology thus allowing opportunity
for a healthy debate.
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